- Home
- ABOS vs CRVS Comparison
ABOS vs CRVS Comparison
Compare ABOS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- CRVS
- Stock Information
- Founded
- ABOS 1996
- CRVS 2014
- Country
- ABOS United States
- CRVS United States
- Employees
- ABOS N/A
- CRVS N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ABOS Health Care
- CRVS Health Care
- Exchange
- ABOS Nasdaq
- CRVS Nasdaq
- Market Cap
- ABOS 72.7M
- CRVS 305.4M
- IPO Year
- ABOS 2021
- CRVS 2016
- Fundamental
- Price
- ABOS $1.49
- CRVS $4.30
- Analyst Decision
- ABOS Strong Buy
- CRVS Strong Buy
- Analyst Count
- ABOS 4
- CRVS 4
- Target Price
- ABOS $6.50
- CRVS $15.00
- AVG Volume (30 Days)
- ABOS 623.5K
- CRVS 1.1M
- Earning Date
- ABOS 08-12-2025
- CRVS 08-05-2025
- Dividend Yield
- ABOS N/A
- CRVS N/A
- EPS Growth
- ABOS N/A
- CRVS N/A
- EPS
- ABOS N/A
- CRVS N/A
- Revenue
- ABOS N/A
- CRVS N/A
- Revenue This Year
- ABOS N/A
- CRVS N/A
- Revenue Next Year
- ABOS N/A
- CRVS N/A
- P/E Ratio
- ABOS N/A
- CRVS N/A
- Revenue Growth
- ABOS N/A
- CRVS N/A
- 52 Week Low
- ABOS $0.86
- CRVS $1.92
- 52 Week High
- ABOS $3.60
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- ABOS 58.51
- CRVS 53.94
- Support Level
- ABOS $1.12
- CRVS $3.79
- Resistance Level
- ABOS $1.27
- CRVS $4.31
- Average True Range (ATR)
- ABOS 0.06
- CRVS 0.29
- MACD
- ABOS 0.00
- CRVS 0.00
- Stochastic Oscillator
- ABOS 77.78
- CRVS 72.64
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).